A federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman’s risk of breast cancer.
一家联邦上诉法院推翻了之前的决定，裁定Myriad Genetics公司确实可以对两种有助于预测女性患乳腺癌风险的基因持有专利。
The chief executive of Myriad, a company in Utah, said the ruling was a blessing to firms and patients alike.
这家位于犹他州的Myriad公司首席执行官表示，这一裁决对公司和患者来说都是福音。
The Myriad case itself is probably not over.
Myriad案本身可能还没有结束。
Critics make three main arguments against gene patents: a gene is a product of nature, so it may not be patented; gene patents suppress innovation rather than reward it; and patents’ monopolies restrict access to genetic tests such as Myriad’s.
批评者对基因专利提出了三个主要论点：基因是自然产物，因此可能无法申请专利；基因专利抑制了创新，而非奖励创新；专利的垄断限制了像Myriad这样的基因检测的获取途径。
In October the Department of Justice filed a brief in the Myriad case, arguing that an isolated DNA molecule “is no less a product of nature…than are cotton fibres that have been separated from cotton seeds.
10月份，司法部在Myriad案件中提交了一份简要文件，主张一个孤立的DNA分子“与从棉花种子中分离出来的棉花纤维一样，都是自然产物……”。
例句取自历年考研英语真题，翻译为机器生成，仅供学习参考。